Posts

GPS nanoparticle platform precisely delivers therapeuti...

UNIVERSITY PARK, Pa. — A newly developed “GPS nanoparticle” injected intravenous...

Have metalenses expanded their reach into the ultraviol...

Ultraviolet rays find diverse applications in medical and healthcare, serving pu...

What’s next for AAV gene therapies in 2024?

Upcoming regulatory events for pipeline AAV gene therapies, with a focus on neur...

Opinion: STAT readers on new CDC Covid guidelines, weig...

In letters to the editor, high-risk people express concern about the CDC’s new C...

Deciphering the tip of migrating neurons: Discovery of ...

The structure and functions of the tip of migrating neurons remain elusive. Here...

Land or sea? Scientists reveal effect of land condition...

Tokyo, Japan – Researchers from Tokyo Metropolitan University have used numerica...

AD/PD 2024: TauRx’s HMTM promising despite lacking prim...

Participants cannot remain blind to their treatment arm due to the properties of...

AD/PD 2024: exploring cutting-edge therapies for ALS

While some biotechs are attempting to develop disease-modifying therapies for am...

FDA delays action on Lilly’s donanemab, intent on advis...

While Lilly’s Alzheimer’s drug was previously expected in Q1 2024, an FDA-mandat...

BeiGene secures accelerated FDA approval for follicular...

The FDA has already granted accelerated approvals to several third-line treatmen...

AD/PD 2024: Vaxxinity reveals Phase I success with Park...

The company revealed the data at the Alzheimer’s Disease and Parkinson’s Disease...

Amylyx considers scrapping ALS drug following Phase III...

Amylyx’s stocks plummeted by more than 85% after announcing it is considering sc...

Oligonucleotides: Overcoming sustainability challenges ...

CPI’s new Oligonucleotide Manufacturing Innovation Centre of Excellence in Scotl...

SK bioscience to expand vaccine manufacturing plant in ...

SK bioscience has broken ground on a significant expansion of its vaccine manufa...

Johnson & Johnson acquires Ambrx Biopharma for $2bn

Johnson & Johnson (J&J) has concluded the acquisition of Ambrx Biopharma in a tr...

FDA approves BMS’ Opdivo for urothelial carcinoma

The US FDA has granted approval for BMS' Opdivo for the first-line treatment of ...